Provided by Tiger Trade Technology Pte. Ltd.

Krystal Biotech Inc.

334.83
-5.2050-1.53%
Volume:74.52K
Turnover:24.94M
Market Cap:9.91B
PE:42.03
High:339.01
Open:339.01
Low:331.79
Close:340.03
52wk High:382.54
52wk Low:151.88
Shares:29.60M
Float Shares:23.54M
Volume Ratio:0.64
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.97
EPS(LYR):6.84
ROE:20.12%
ROA:9.37%
PB:7.29
PE(LYR):48.95

Loading ...

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

GlobeNewswire
·
May 21

Krystal Biotech shareholders elected Krishnan, Mason as Class III directors

Reuters
·
May 20

Krystal Biotech announces UK MHRA approval of Vyjuvek

TIPRANKS
·
May 18

Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa

Reuters
·
May 18

Krystal Biotech Announces United Kingdom Mhra Approval of Vyjuvek® for the Treatment of Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
May 18

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire
·
May 18

The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability

Simply Wall St.
·
May 18

Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)

TIPRANKS
·
May 18

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

MT Newswires Live
·
May 16

U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

TIPRANKS
·
May 16

BRIEF-UK's MHRA Approves Beremagene Geperpavec For Treatment Of Dystrophic Epidermolysis Bullosa

Reuters
·
May 16

UK's Mhra: Mhra Approves Beremagene Geperpavec (Vyjuvek) for Treatment of Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
May 16

Analysts Conflicted on These Healthcare Names: RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech (KRYS)

TIPRANKS
·
May 14

Krystal Biotech Inc : Bofa Global Research Raises Price Objective to $364 From $323

THOMSON REUTERS
·
May 14

There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings

Simply Wall St.
·
May 14

Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed?

Simply Wall St.
·
May 11

Krystal Biotech to present at BofA Securities Health Care Conference fireside chat

Reuters
·
May 07

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Benzinga Earnings
·
May 06

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

TIPRANKS
·
May 05

Stock Track | Krystal Biotech Soars 5.25% Intraday on Strong Q1 Earnings Beat and FDA RMAT Designation

Stock Track
·
May 04